Cubist Submits CTA to Dutch Competent Authority and Ethics Committee to Initiate First-in-Human Study of CB-618

Cubist Pharmaceuticals

today announced that it submitted a Clinical Trial Application (CTA) to the Dutch Competent Authority and Ethics Committee to initiate a first-in-human study of CB-618 in the Netherlands. Discovered by Cubist, CB-618 is a novel, broad-spectrum beta-lactamase inhibitor (BLI) investigational compound. Based on in vitro studies, CB-618 has been shown to increase the spectrum of activity of certain beta-lactam antibiotics. (Beta-lactamases are enzymes produced by some bacteria that provide resistance to certain beta-lactam antibiotics.)